BE2013C046I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C046I2
BE2013C046I2 BE2013C046C BE2013C046C BE2013C046I2 BE 2013C046 I2 BE2013C046 I2 BE 2013C046I2 BE 2013C046 C BE2013C046 C BE 2013C046C BE 2013C046 C BE2013C046 C BE 2013C046C BE 2013C046 I2 BE2013C046 I2 BE 2013C046I2
Authority
BE
Belgium
Application number
BE2013C046C
Other languages
French (fr)
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of BE2013C046I2 publication Critical patent/BE2013C046I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
BE2013C046C 2002-10-10 2013-07-03 BE2013C046I2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41759002P 2002-10-10 2002-10-10
PCT/EP2003/011212 WO2004032938A1 (en) 2002-10-10 2003-10-09 Use of dihydroimidazolones for the treatment of epilepsy in dogs

Publications (1)

Publication Number Publication Date
BE2013C046I2 true BE2013C046I2 (ko) 2022-08-09

Family

ID=32094042

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C046C BE2013C046I2 (ko) 2002-10-10 2013-07-03

Country Status (28)

Country Link
US (5) US20050070537A1 (ko)
EP (3) EP2845594B1 (ko)
JP (4) JP4694202B2 (ko)
KR (2) KR101110587B1 (ko)
CN (2) CN1726040B (ko)
AR (1) AR041573A1 (ko)
AT (1) ATE418337T1 (ko)
AU (2) AU2003273978B2 (ko)
BE (1) BE2013C046I2 (ko)
BR (1) BR0315225A (ko)
CA (2) CA2727722C (ko)
CY (3) CY1109961T1 (ko)
DE (1) DE60325496D1 (ko)
DK (2) DK2845594T3 (ko)
ES (2) ES2908453T3 (ko)
FR (2) FR13C0044I2 (ko)
HK (1) HK1085920A1 (ko)
HR (3) HRP20090667B1 (ko)
HU (2) HUS1300035I1 (ko)
LU (1) LU92238I2 (ko)
MX (1) MXPA05003663A (ko)
NZ (1) NZ539864A (ko)
PL (2) PL238776B1 (ko)
PT (2) PT2845594T (ko)
SI (2) SI2845594T1 (ko)
TW (2) TWI324067B (ko)
WO (1) WO2004032938A1 (ko)
ZA (1) ZA200502245B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
EP1646386A2 (en) * 2003-07-11 2006-04-19 elbion AG Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
EP3318247A1 (en) 2011-08-12 2018-05-09 Boehringer Ingelheim Vetmedica GmbH Taste masked pharmaceutical composition
JP6193613B2 (ja) * 2013-05-10 2017-09-06 学校法人麻布獣医学園 てんかん発作のモニタリングシステム及びモニタリング方法
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
US9856250B2 (en) 2014-05-28 2018-01-02 Toa Eiyo Ltd. Substituted tropane derivatives
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017218629A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
US5869481A (en) * 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19532668A1 (de) * 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
WO1999000346A1 (en) 1997-06-26 1999-01-07 Board Of Regents, The University Of Texas System Synthesis of dihydrohonokiol compositions
JP4669095B2 (ja) * 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
DK1485094T4 (da) 2002-03-07 2020-06-22 Boehringer Ingelheim Int Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP3318247A1 (en) 2011-08-12 2018-05-09 Boehringer Ingelheim Vetmedica GmbH Taste masked pharmaceutical composition
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
US20150072983A1 (en) 2015-03-12
FR13C0044I1 (ko) 2013-08-30
AU2003273978A1 (en) 2004-05-04
PL214702B1 (pl) 2013-09-30
ZA200502245B (en) 2005-11-30
TWI324067B (en) 2010-05-01
DE60325496D1 (de) 2009-02-05
US20080027057A1 (en) 2008-01-31
TWI424849B (zh) 2014-02-01
SI2845594T1 (sl) 2022-04-29
WO2004032938A1 (en) 2004-04-22
US9469611B2 (en) 2016-10-18
HUS1300035I1 (hu) 2017-10-30
AU2003273978B2 (en) 2009-07-23
TW200503726A (en) 2005-02-01
JP2016104817A (ja) 2016-06-09
HRP20090667A2 (hr) 2010-07-31
HRP20050322B1 (hr) 2013-12-06
CY1125103T1 (el) 2023-01-05
FR22C1033I1 (fr) 2022-09-09
SI1553952T1 (sl) 2009-04-30
US8962617B2 (en) 2015-02-24
CA2501772C (en) 2011-08-23
CN101890019A (zh) 2010-11-24
ES2908453T3 (es) 2022-04-29
KR20110063843A (ko) 2011-06-14
CN1726040A (zh) 2006-01-25
PL397320A1 (pl) 2012-02-13
JP2006503873A (ja) 2006-02-02
CY2013031I2 (el) 2015-11-04
HRP20050322A2 (en) 2006-05-31
CA2501772A1 (en) 2004-04-22
PL374603A1 (en) 2005-10-31
KR20050056237A (ko) 2005-06-14
EP2845594A1 (en) 2015-03-11
ES2316808T3 (es) 2009-04-16
US20160367562A1 (en) 2016-12-22
DK1553952T3 (da) 2009-04-20
EP1553952B1 (en) 2008-12-24
EP2845594B1 (en) 2022-02-23
PL238776B1 (pl) 2021-10-04
PT2845594T (pt) 2022-03-09
CA2727722A1 (en) 2004-04-22
CN1726040B (zh) 2010-05-12
US20050070537A1 (en) 2005-03-31
BR0315225A (pt) 2005-08-23
LU92238I9 (ko) 2019-01-09
PT1553952E (pt) 2009-02-10
HRP20200207A2 (hr) 2020-07-24
FR13C0044I2 (fr) 2014-03-07
LU92238I2 (fr) 2013-09-03
MXPA05003663A (es) 2005-06-08
HUS2200036I1 (hu) 2022-08-28
DK2845594T3 (da) 2022-03-07
NZ539864A (en) 2007-11-30
JP6249812B2 (ja) 2017-12-20
HRP20090667B1 (hr) 2021-06-11
US8859540B2 (en) 2014-10-14
EP1553952A1 (en) 2005-07-20
CA2727722C (en) 2013-05-28
EP2036563A1 (en) 2009-03-18
JP2014080449A (ja) 2014-05-08
CY2013031I1 (el) 2015-11-04
ATE418337T1 (de) 2009-01-15
AU2009225322A1 (en) 2009-11-05
AR041573A1 (es) 2005-05-18
US20130065898A1 (en) 2013-03-14
JP4694202B2 (ja) 2011-06-08
CY1109961T1 (el) 2014-09-10
JP2011068685A (ja) 2011-04-07
HK1085920A1 (en) 2006-09-08
TW201010706A (en) 2010-03-16
KR101110587B1 (ko) 2012-02-15

Similar Documents

Publication Publication Date Title
BE2019C547I2 (ko)
BE2019C510I2 (ko)
BE2018C021I2 (ko)
BE2017C049I2 (ko)
BE2017C005I2 (ko)
BE2016C069I2 (ko)
BE2016C040I2 (ko)
BE2016C013I2 (ko)
BE2018C018I2 (ko)
BE2016C002I2 (ko)
BE2015C078I2 (ko)
BE2015C017I2 (ko)
BE2014C053I2 (ko)
FR14C0060I1 (ko)
BE2014C041I2 (ko)
BE2014C030I2 (ko)
BE2014C016I2 (ko)
BE2014C015I2 (ko)
DE60229073D1 (ko)
BE2011C038I2 (ko)
BRPI0302144A2 (ko)
BRPI0215435A2 (ko)
BE2013C046I2 (ko)
JP2002347633A5 (ko)
JP2003208766A5 (ko)